Sensorygen, Inc

Huntington Medical Research Institutes is nonprofit, public-benefit organization dedicated to improving health and prolonging life by enhancing knowledge of life processes and disease and developing technology to diagnose and treat diseases. Its developments include the hydrocephalus shunt to treat water-on-the-brain, studies on biomedical applications of laser energy, cancer research, electronic neural rehabilitation technology and applications of medical magnetic resonance imaging and spectroscopy. Huntington Medical Research Institutes was founded in 1952 and operates in five locations in Pasadena, Calif.

Balto Pharmaceuticals Inc, located in South Pasadena, CA, is dedicated to enhancing patient outcomes through the development of innovative small molecule inhibitors that target protein-protein interactions. Their mission centers on creating safe and effective treatments for cancer, aiming to pioneer advancements in the field of oncology. Committed to improving treatment options, Balto Pharmaceuticals focuses on producing first-in-class therapies that promise significant benefits for patients. The company strives to lead the way in transforming cancer care through its specialized research and development efforts. Generated from the website

Genervon Biopharmaceuticals is a clinical-stage biopharmaceutical company based in Pasadena, CA, dedicated to pioneering innovative approaches to drug development for complex neurological disorders. With a focus on multi-target drug development, the company has synthesized GM6, a peptide that passes through the blood-brain barrier, aiming to improve clinical outcomes for conditions such as ALS, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. For over twenty years, Genervon has been committed to research and development in the pursuit of curative therapies for neurodegenerative diseases, utilizing a master regulatory approach to address the common underlying pathophysiology of these disorders. The company is actively seeking partners to advance GM6 from its development phase into a marketable therapy for patients in need. Generated from the website